Acadia Pharmaceuticals Inc

NASDAQ: ACAD
$14.79
-$0.06 (-0.4%)
Closing price May 17, 2024

ACAD Articles

A new report from the analysts at Cowen shows that, on average, biotech stocks gained 84% in the 12 months prior to an FDA approval and lost 24% in the 12 months after the approval.
U.S. equity markets opened higher this morning following some mixed economic data released in China. The country’s CPI rose less than expected, producer prices fell, fixed asset investment rose a...
Source: thinkstockHere are today’s five biggest gaining stocks at closing:ACADIA Pharmaceuticals inc. (NASDAQ: ACAD) is up 64.4% at $13.10.Rite Aid Corp. (NYSE: RAD) is up 18.4% at $2.12.Metalico...
U.S. equity markets opened flat to lower this morning following yesterday’s record-setting session. Economic data was minimal today. In Asia, machinery orders rose more than expected in Japan, but...
Source: thinkstockHere are today’s five biggest gaining stocks at closing:Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) is up 26% at $4.84.ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is up 23.9% at...
U.S. equity markets opened lower this morning and trailed slowly downward all day. The situation in Cyprus was unchanged this morning (more coverage here). In Europe, both manufacturing and...
U.S. equity markets opened lower again this morning, even following an agreement on the amount and delivery date of another eurozone bailout package for Greece (more coverage here). The lack of...
The stock market is down Tuesday, with the Dow Jones Industrial Average down 0.24%, the Nasdaq down 0.26% and the S&P 500 down 0.23%. Today’s winners include a pharmaceutical firm which...
Source: ThinkstockACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is proving to be the big winner of the day. In fact, it may be the winner of the month on any percentage gain in a day. Its shares are up...
We are seeing many news-related movers in today’s edition of the BioHealth Business Daily.  ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), Adeona Pharmaceuticals, Inc. (AMEX: AEN), Dendreon...
These aren’t all of the analyst calls out there today, but these are ten of the calls impacting shares early this Tuesday morning: ACADIA Pharmaceuticals (ACAD) Raised to Neutral at Banc of...
Pilgrim’s Pride (PPC) Downgraded by Credit Suisse. Down to $15.67 from 52-week high of $41. Pepsi Bottling Group (PBG) Still troubled by problems at one of Coke’s bottlers. Down to $29.22...
If you thought biotech news was getting quiet going into earnings season, think again. Acadia Pharmaceuticals Inc. (ACAD) presents Phase II data on pimavanserin, a treatment  for Parkinson’s...
ACAD started as Outperform at FBR.ALC started as Outperform at RBC.ARUN started as Buy at Jefferies.ATVI started as Buy at First Albany.AZ raised to Buy at UBS.CHA cut to Hold at Deutsche Bank.DRIV...
On tonight’s Mad Money on CNBC, Jim Cramer had his normal ‘Speculation Friday’ and talked CV Therapeutics (CVTX) for a speculative biotech in with Acadia (ACAD) and Nastech...